MASI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
["Not a good buy right now: price action is in a clear downtrend (SMA200 > SMA20 > SMA5) with weakening momentum (MACD histogram negative and expanding).", "The stock is sitting near support (~134.8); while a short-term bounce is possible, there is no proprietary buy signal and no near-term catalyst/news to justify an impatient entry today.", "Better as a wait/hold setup into a confirmed reversal or a clear catalyst (next earnings 2026-02-23) rather than buying immediately."]
["Trend: Bearish; moving averages are stacked negatively (SMA_200 > SMA_20 > SMA_5), indicating sustained downside bias.", "Momentum: MACD histogram -0.404 below zero and negatively expanding \u2192 selling pressure is increasing, not stabilizing.", "RSI(6)=33.7: approaching oversold territory; this can support a tactical bounce, but it is not a reversal signal by itself.", "Key levels: S1=134.811 is effectively being tested (current 134.41). Next support S2=132.308. Overhead pivot/resistance at 138.862 then R1=142.913.", "Pattern-based forward look (similar candlesticks): slight negative bias next week (-1.05%) and only modest upside over a month (+1.05%)\u2014not strong enough to override the current downtrend."]
highlight confidence in multi-year growth trajectory.", "Revenue growth is still positive (2025/Q3 revenue +8.21% YoY) with slightly improved gross margin (62.07%, +0.47% YoY).", "Upcoming catalyst: QDEC 2025 earnings on 2026-02-23 (after hours) could re-rate the stock if profitability and guidance improve."]
["Technical setup is weak: bearish MA stack and deteriorating MACD reduces odds of a clean near-term upside follow-through.", "Latest quarter profitability shock: 2025/Q3 net income -$100.4M and EPS -1.86 (large YoY deterioration) raises concern that the stock may stay range-bound/under pressure until clarity improves.", "No supportive near-term news flow in the past week; without an event catalyst, price is more likely to respect the current downtrend.", "Options tape today is defensively skewed (put-heavy volume), consistent with caution into the next catalyst window."]
["Latest reported quarter: 2025/Q3.", "Revenue: $371.5M, up 8.21% YoY (solid top-line growth).", "Profitability: Net income -$100.4M (down -1124.49% YoY) and EPS -1.86 (down -1133.33% YoY) \u2014 major negative swing that outweighs revenue growth in the near term.", "Margins: Gross margin 62.07%, up 0.47% YoY (slight improvement, but not enough to offset the earnings deterioration)."]
["Recent trend: price targets have moved higher from bullish firms after Investor Day (Wells Fargo to $190 Overweight; BTIG to $200 Buy).", "Coverage addition: BofA initiated at Neutral with a $162 target (more cautious stance).", "Wall Street pros/cons view: Pros\u2014confidence in multi-year growth and product cycle, potential for consistent MedTech performance. Cons\u2014mixed conviction across the Street (Neutral initiation) and the market will likely demand proof of improved profitability after the sharp EPS/net income drop.", "Institutional/insider tone: hedge funds and insiders are described as Neutral with no significant recent trend; no politician/congress trading data available in the last 90 days."]
